Early Hyperprogression of Rhabdomyosarcoma Detected by 18F-FDG PET/CT Three Weeks after CAR-T Treatment
World Journal of Nuclear Medicine · 01.09.2024 · 23 (03) · 212-216
DOI: 10.1055/s-0044-1787537 ↗Kurz gefasst
Fallbericht in der Zeitschrift World Journal of Nuclear Medicine, erschienen am 01.09.2024. Verfasst von Shenrui Guo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chimeric antigen receptor T-cell (CAR-T) treatment has been widely used in the treatment of hematological malignancies, and its application has been gradually expanded to the research and treatment of solid tumors. However, unconventional types of response may occur after CAR-T treatment, such as hyperprogression, resulting in terrible outcomes. Here, we report the case of a 13-year-old adolescent boy with relapsed and refractory rhabdomyosarcoma who developed early hyperprogression 3 weeks after CAR-T treatment (target: B7H3 and CD171), which was detected by fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT). The patient eventually underwent amputation. Attention should be paid to the possibility of early hyperprogression after CAR-T treatment, and 18F-FDG PET/CT has an absolute advantage in early evaluating treatment response to immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Pediatric Hematology/Oncology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Pathology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Yafu Yin
Zitieren
APA
Guo, S., Tan, Z., Guan, W., & Yin, Y. (2024). Early Hyperprogression of Rhabdomyosarcoma Detected by 18F-FDG PET/CT Three Weeks after CAR-T Treatment. World Journal of Nuclear Medicine, 23(03), 212-216. https://doi.org/10.1055/s-0044-1787537
Vancouver
Guo S, Tan Z, Guan W, Yin Y. Early Hyperprogression of Rhabdomyosarcoma Detected by 18F-FDG PET/CT Three Weeks after CAR-T Treatment. World Journal of Nuclear Medicine. 2024;23(03):212-216. doi:10.1055/s-0044-1787537
BibTeX
@article{Guo2024,
author = {Guo, Shenrui and Tan, Zhen and Guan, Wenbin and Yin, Yafu},
title = {Early Hyperprogression of Rhabdomyosarcoma Detected by 18F-FDG PET/CT Three Weeks after CAR-T Treatment},
journal = {World Journal of Nuclear Medicine},
year = {2024},
volume = {23},
number = {03},
pages = {212--216},
doi = {10.1055/s-0044-1787537}
}
EUVIMED